Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection - Archive ouverte HAL Access content directly
Preprints, Working Papers, ... Year :

Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection

(1) , (1) , (1) , (1) , (1) , (2) , (3) , (1) , (4) , (4) , (5) , (5, 6) , (7) , (4) , (8) , (8) , (9) , (5) , (4) , (5, 10) , (1)
1
2
3
4
5
6
7
8
9
10
Sandrine Le Guellec
  • Function : Author
Laurie Lajoie
Christopher Alabi

Abstract

Abstract Measles is the most contagious airborne viral infection and the leading cause of child death among vaccine-preventable diseases. We show here that aerosolized lipopeptide fusion inhibitors, derived from heptad-repeat regions of the measles virus (MeV) fusion protein, block respiratory MeV infection in a non-human primate model, the cynomolgus macaque. We used a custom-designed mesh nebulizer to ensure efficient aerosol delivery of peptides to the respiratory tract and demonstrated the absence of adverse effects and lung pathology in macaques. The nebulized peptide efficiently prevented MeV infection, resulting in the complete absence of MeV RNA, MeV-infected cells, and MeV-specific humoral responses in treated animals. This strategy provides an additional shield which complements vaccination to fight against respiratory infection, presenting a proof-of-concept for the aerosol delivery of fusion inhibitory peptides to protect against measles and other airborne viruses, including SARS-CoV-2, in case of high-risk exposure, that can be readily translated to human trials.
Fichier principal
Vignette du fichier
v1_covered.pdf (2.79 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03777084 , version 1 (20-10-2022)

Identifiers

Cite

Olivier Reynard, Claudia Gonzalez, Claire Dumont, Mathieu Iampietro, Marion Ferren, et al.. Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection. 2022. ⟨hal-03777084⟩
16 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More